Overview
Primary Objective:
- To describe dupilumab health-related quality of life (HRQoL) effectiveness at 52 weeks compared to baseline.
Secondary Objectives:
- To describe dupilumab HRQoL effectiveness at 12 and 24 weeks compared to baseline.
- To assess the safety during the year of treatment in a real-world setting.
Eligibility
Inclusion Criteria:
- Participant must be at least 18 years of age inclusive, at the time of signing the informed consent.
- Participant for whom decision of initiation and prescription of dupilumab (Dupixent®) for the severe uncontrolled asthma indication was made by the investigator within four weeks before the inclusion in the study. Oral CorticoSteroid (OCS) or non-OCS-dependent patient could be included.
- Participant for whom St. George's Respiratory Questionnaire (SGRQ) score is available within the last 4 weeks prior to dupilumab initiation. SGRQ score could be collected at baseline visit for participants who have not yet started dupilumab.
- Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion Criteria:
- Participant below 18 years of age. - Participant participating in a clinical trial at the time of enrolment.
- Participant under guardianship, trusteeship or under judicial protection.
The above information is not intended to contain all considerations relevant to a potential
participation in a clinical trial.